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Objective. The purpose of this study was to determine whether several
quantitative ultrasonographic measures have potential to discriminate
prostate cancer from normal prostate and to determine the best combination
of these measures. The true spatial distributions of cancer within the
prostates studied were obtained histologically after radical prostatectomy. The
relationship between Doppler ultrasonography and microvessel count was
also investigated. Methods. Three-dimensional Doppler ultrasonographic
data were acquired from 39 patients before radical prostatectomy. The
removed prostate was sectioned, and whole-mount hematoxylin-
eosin–stained slides were used to identify all regions of cancer within each
prostate. These histologic and ultrasonographic data were spatially registered.
Doppler ultrasonographic measures were calculated within uniformly sized
three-dimensional regions that were either entirely cancerous or noncancer-
ous, and receiver operating characteristic analysis was performed on the
results. Microvessel counts were made within each contiguous cancerous
region and correlated with ultrasonographic measures. Results. Color pixel
density was the best simple measure for discriminating prostate cancer (accu-
racy, 80%). The mean power mode value (normalized mean power in color
pixels) was inversely related to cancer with an accuracy of 1 – normalized
mean power in color pixels = 65% (low mean power is more cancerous).
When color pixel density was combined with the normalized mean power in
color pixels, its accuracy improved slightly to 84%. The peak microvessel
count had a negative correlation with color pixel density as well as with can-
cer stage. Conclusion. Doppler ultrasonography does provide discriminatory
information for prostate cancer, with color pixel density being the most
promising measure. Key words: prostate, ultrasonography; prostate, neo-
plasms; ultrasonography, three-dimensional; ultrasonography, Doppler stud-
ies; ultrasonography, comparative studies; ultrasonography, power Doppler
studies.
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Article
rostate cancer is the most frequently diag-
nosed cancer in men. In North America it
has the highest mortality rate of all can-
cers in men except for lung cancer.1 When
prostate cancer is diagnosed early, it is usually
curable. Treatment is often effective even at later
stages. Therefore, the decision of who and when
to treat for prostate cancer is very important.
These decisions are not made easily for 2 rea-
sons. First, prostate cancer is highly prevalent. As
much as 30% of the male population older than
50 years have prostate cancer found at autopsy.2
Second, prostate cancer progresses relatively
slowly. Of the 30% with prostate cancer found at
autopsy, most died of other causes, and the can-
cer detected was typically of a volume of less
than 0.5 cm3. Therefore, detection of prostate
cancer alone does not mean the best course of
action is treatment. The stage and aggressiveness
of the cancer also must be taken into account.
The current methods of prostate cancer diag-
nosis do not adequately provide the information
needed to make informed treatment decisions.
Diagnostic techniques include transrectal ultra-
sonography, prostate-specific antigen measure-
ment, and transrectal needle biopsy. Currently,
B-mode ultrasonography is used to look for
hypoechoic regions of the prostate. However, not
all cancer appears hypoechoic, especially the
smaller masses.3 Prostate-specific antigen pro-
duction can also be influenced by factors such as
acute prostatitis, acute urinary retention, rigid
cytoscopy, transrectal ultrasonography, trans-
rectal needle biopsy, surgery, and ejaculation.2 A
biopsy core cannot provide information about
the extent or prevalence of the cancer. Because of
this, there is some debate as to how many biop-
sies are adequate for a given patient.4
Doppler ultrasonography, both power mode and
frequency shift, has also been studied for diagno-
sis of prostate cancer. The rationale for using color
flow imaging is that cancer will develop an
increased blood supply by angiogenesis, and this
can show up as increased and abnormal color flow
patterns in and around the cancerous regions.
In the prostate, color flow imaging has been
tried with simple visual staging schemes. This
technique has had some success in discriminat-
ing cancer from benign tissue5 and in determin-
ing cancer prognosis.6,7 More recently a study
was done in which hypervascular lesions as seen
on power Doppler imaging correlated with
increases in biopsy yields.8
This study was designed to evaluate several dif-
ferent components of Doppler ultrasonographic
information as discriminators for prostate can-
cer. The purposes behind the results of the study,
therefore, were to provide some insight into what
information provided by Doppler imaging may
be useful for this task and to point the way
toward an effective ultrasonographic diagnostic
tool for prostate cancer. However, this study was
not designed to determine the efficacy of
Doppler ultrasonography in any specific clinical
context.
Additionally, in this study we investigated the
relationship between quantitative ultrasono-
graphic measures and peak microvessel counts
from the same cancerous region to determine
whether the information seen on Doppler ultra-
sonography is related to the location of the small-
est vessels as seen on histologic examination.
Materials and Methods
Study Population
Fifty-two patients who were to undergo radical
prostatectomy were recruited for this study. For
12 patients, 1 or more of the three-dimensional
(3D) data sets required for analysis were missing;
consequently, these 12 patients were excluded.
No cancer was found in another patient after
prostatectomy. Four patients were treated hor-
monally before this study, but excluding them
from the data set did not significantly alter the
results.
All patients included in this study were referred
to the local department of urology for radical
prostatectomy as part of their treatment. This
study was not racially screened; nevertheless, all
subjects were white. Institutional Review Board
approval was obtained, as was informed consent
from all patients before ultrasonography.
Acquisition
The first step was to gather the raw volume
data necessary to compute the various ultra-
sonic measures and to histologically identify
cancerous regions. Data volumes acquired in
this study included the in vivo frequency shift
and power mode ultrasonographic scans, the
images of the histologic hematoxylin-eosin 
(H & E)–stained slides, the factor VIII–stained
slides, and the in vitro ultrasonographic scans
used to register the histologic images with the
in vivo scans (Fig. 1).
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The frequency shift scan was acquired with an
ATL HDI 3000 system (ATL Ultrasound, Bothell,
WA) using a C9-5 transrectal probe. In a 3D scan
of the prostate, the transducer was rotated so
that the scan plane swept through the entire
prostate; the axis of rotation was positioned at
the anus for minimum discomfort. The appara-
tus described by Moskalik et al9 was developed
to acquire the desired in vivo image slices in a
stable, reproducible way so that scan slices can
later be reconstructed in the correct geometric
configuration.
The physician conducting the scan manually
controlled the angular position. A digital readout
displayed the relative angular position of the
probe from the beginning of the scan. At fixed
increments of 0.54°, the color flow image at that
position was saved as a TIFF file to the internal
hard disk of the ATL system. The acquired image
was selected manually at peak systole. For larger
prostates, the increment was increased to 0.72°
to keep the scan time short and to reduce
patient discomfort. The scan plane was oriented
sagittally and was rotated in this manner from
right to left through the prostate so that the
entire gland was imaged.
The settings of the ATL system were kept con-
sistent for all scans. On the basis of the experi-
ence of the radiologists involved in this study,
the following settings were used. The general
prostate preset was selected. The pulse repeti-
tion frequency was set to 1000 Hz for the fre-
quency shift scan and 700 Hz for the power
mode scan. The gain was occasionally adjusted
to reduce noise, but typically it was set to 70% for
frequency shift and 84% for power mode. The
wall filter settings were low and medium for fre-
quency shift and power mode, respectively.
Persistence and frame rate were set at medium,
and the sensitivity was set at high.
After the in vivo scans of the prostate, the
ultrasonographic volume data existed as a
series of TIFF images. The color flow informa-
tion was encoded in these images as different
red-green-blue values whose power or velocity
value was assigned in a color bar along the side
of each image. This color information was writ-
ten over the gray scale B-mode information.
The power mode and frequency shift infor-
mation encoded in the color part of the images
was the raw form of the data that were to be
correlated with the histologic data. The gray
scale B-mode part of the images was needed
for the spatial registration of the ultrasono-
graphic images with the histologic slides.
The first processing step for the raw in vivo
images was to separate the color information
from the gray scale information and to decode
the red-green-blue color information into the
scalar intensity or speed by using the color bar.
The next step was to reconstruct the images,
which were acquired by an angular sweep, into
a rectilinear field. Finally, color artifacts such
as the reverberation found behind calcifica-
tions were removed from the color flow data.
This was accomplished by using custom soft-
ware written in the AVS/Express (Advanced
Visual Systems, Waltham, MA) environment.
After the prostate was surgically removed and
placed in a stabilizing holder for positioning
and sectioning, it was rescanned in vitro by
using the HDI 3000 system with the same C9-5
probe used for the in vivo scans. The prostate
was scanned linearly with evenly spaced slice
planes (0.5-mm spacing) in the same orienta-
tion and essentially the same planes as for the
histologic sections. This made it easier to later
align the histologic slides by using the in vitro
scan.
The prostate was then sliced into 3-mm sec-
tions in the same transverse orientation. From
each of these sections, an H & E–stained slide
was made. On the H & E–stained slide, the can-
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Figure 1. The prostate is shown in its anatomic position. The
ultrasonic probe was inserted transrectally and produced
images of the area shown in gray above. The probe was rotat-
ed at the anus from left to right, so that the entire prostate was
imaged. After prostatectomy, the gland was ultrasonographi-
cally imaged and sectioned in the orientation shown by the
gray lines.
cerous lesions were outlined and graded by a
urologic pathologist.
The left, right, and posterior aspects were also
labeled. This information coupled with the in
vitro ultrasonographic scan was used to align
the images of the histologic slides into a 3D vol-
ume. Matching the position of the urethra on
adjacent slides further refined the alignment of
the slides.
The next step was to form a 3D field where the
voxels within each cancerous volume were
labeled. The cancer outline markings were
selected by a filter, and the cancer volumes were
filled in. Each individual cancer volume was
then assigned a different label. Adjacent cancer-
ous regions from different slides were given the
same label. This provided a 3D mapping of
where the cancer was located. The region
extending 0.5 cm out from each cancerous
region was also uniquely labeled in this map.
Registration
A manual registration technique was developed
to spatially align the ultrasonographic and histo-
logic data sets.10 This technique modeled the
prostate with an ellipsoid that could be used to
generate an affine transform matrix (Fig. 2).
The power mode data volume was used as the
reference volume onto which the frequency shift
and histologic data volume was registered. The
transform for either of these 2 registrations was
computed by multiplying the inverse transform
of the power mode ellipsoid definition matrix by
the ellipsoid definition matrix from the frequen-
cy shift or histologic volume.
A reconstructed volume was generated for the
frequency shift and the histologic data, with the
3D field identical in size to the power mode field.
The value of each voxel in a reconstructed field
was computed by multiplying the vector posi-
tion of that voxel by the transform matrix. This
process can be represented by the following
equation: 
(1) ,
where 
→
vr was the vector in the reference space
(power mode data set); Eo was the ellipsoidal
matrix of the original prostate volume; Er was the
ellipsoid matrix of the reference prostate; and 
→
vo
was the corresponding position vector in the
original volume.
The transform matrix was refined by directly
comparing the ultrasonographic and histologic
data within the same volume and visually assess-
ing the quality of the registration. Adjustments
were made to the transform matrix accordingly.
The histologically defined cancer mapping
could then be mapped directly onto the ultra-
sonographic data, producing a spatial mapping
that related the color flow data to the identified
cancerous regions.
Quantitative Ultrasonographic Measures
The information used in the quantitative ultra-
sonographic measures can be classified as 2
types: the mean color flow value within a region
and the color flow density within a region. This
coupled with the 2 types of Doppler images
acquired, frequency shift and power mode, pro-
duced 4 basic measures: mean velocity in color
pixels (V), normalized mean power in color pix-
els (NMPCP), color pixel density in frequency
shift (CPDfs), and color pixel density in power
mode (CPDpm). These measures were computed
by the following equations:
(2)
(3)
(4) ,
where Nb was the number of color pixels in the
region of interest; Nt was the total number of
pixels in the region of interest; Vi was the esti-
mated mean velocity of moving particles in the
ith pixel as represented by the color of that
pixel; and Pi was the linearized power value of
the ith pixel. Pb was a threshold value taken to
represent the power signal from a region of
100% blood at a given depth. This value was
used as a normalization factor to correct for
depth dependencies such as attenuation in the
power signal. The normalization factor was
computed in 5 depth zones for each prostate by
using the method described by Rubin et al.11 
Briefly, this method used the cumulative distri-
bution of power mode values found within a
depth zone. The “knee” of this distribution could
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be found reproducibly as a measure of local sig-
nal level. Pb was designed to correspond to the
power value seen in the high sheer region of
large vessels, where it could be reasonably
assumed that any power greater than this knee
value represented 100% blood; i.e., that the
entire voxel was within a large blood vessel with-
out rouleaux. Whether that interpretation was
appropriate for the small vessels studied here
has not been determined. Pb appeared to func-
tion stably as an adjustment for signal level with
depth. Any effect of the absolute value of Pb as a
function of depth was eliminated by the subse-
quent normalization described below.
For frequency shift measures, an isotropic
blood flow direction was assumed within each
Doppler sample volume. This assumption did
not hold for the larger vessels; however, statisti-
cally over all prostate volumes, one would expect
an isotropic distribution, and therefore, our anal-
ysis should not be affected by this assumption.
Average ultrasonographic color flow measures
vary significantly among patients despite care-
fully maintaining consistent machine settings.
This may be due to systemic differences among
patients’ circulation, the timing of the ultrasono-
graphic scan relative to physiologic events such
as ejaculation, and local differences in the circu-
lation to the prostate due to cancer or other dis-
ease. Because these different factors were not
and could not be controlled in this study, they
could not be separated and accounted for indi-
vidually. Therefore, all the quantitative measures
for each prostate were normalized by the value
calculated within the total noncancerous region
of that prostate. All other regions’ measures were
expressed relative to the noncancerous tissue’s
mean value within that prostate.
Further compound measures can be com-
puted by combining the above measures, for
instance, speed-weighted pixel density was 
V ⋅ CPDfs, and normalized power-weighted pixel
density was NMPCP ⋅ CPDpm.
Receiver Operating Characteristic Analysis
The next step was to determine which of these
quantitative measures provided information
that can be used to discriminate cancer from
noncancerous tissue in the prostate and which
measure or combination of measures did this
best. A powerful tool appropriate for this type of
analysis is the receiver operating characteristic
(ROC) curve.12
An ROC curve is essentially a plot of the true-
positive fraction versus the false-positive frac-
tion for a range of threshold values from the
measure being investigated as a discriminator.
An ideal detector would have an ROC curve
with a true-positive fraction of 1 at a false-pos-
itive fraction of 0. The area under this curve
would be 1. A detector that is unrelated (pro-
vides no discrimination) to the quality that is
being discriminated would have an ROC curve
that runs diagonally from (0, 0) to (1, 1) and an
area of 0.5 under it. Real detectors have curves
that fall between these 2 extremes, with better
detectors having a larger area.
To apply this technique to our data, first we
divided each prostate into equally sized vol-
umes (0.8 cm3), which were either entirely
cancerous or entirely noncancerous as
defined by the histologically identified
regions of cancer.13 These volumes were con-
tiguous and as compact as possible. This was
accomplished by using the mapping of
prostate cancer identified on the histologic
slides to define the boundaries between the
cancer and the normal tissue. The 0.5-cm
shell around each cancerous region was
excluded in this analysis.
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Figure 2. Representation of prostate model. A midsagittal slice of the recon-
structed power mode data is shown, with the transparent green ellipsoid shell rep-
resenting the prostate model. The beige line marks the location of the urethra. The
left blue line was drawn at the midline of the ellipsoid. The right blue line connects
the ends of the prostatic urethra. The ellipsoid is positioned so that the angle
between these 2 lines is 30°. The dark B-mode line to the left and roughly parallel
to the urethra is due to the boundary between the peripheral zone and the cen-
tral zone, which can sometimes be easily confused with the urethra. 
The various quantitative measures were com-
puted for each volume from all the prostates.
These data were then fed into the ROC analysis
package ROCkit (Charles Metz, Department of
Radiology, University of Chicago, Chicago, IL).
Microvessel Density
In our study, whole-mount factor VIII–stained
slides were made of each prostate from the 3-
mm sections. A 0.5-cm grid was drawn onto each
slide. By using a method similar to that used by
Weidner et al,14 microvessel counts were made.
Within each grid square that contained cancer, a
region was selected at low microscopic power
that contained the visually greatest amount of
endothelial stain. This area was then examined at
×200 magnification, and the number of distin-
guishable microvessels was counted. Likewise, a
count was made in the area outside the cancer
within this square. In addition, a count was made
within 5 noncancerous squares on each slide.
This resulted in a number of counts for each can-
cerous volume and the noncancerous portion of
each prostate (1 count per 0.5-cm square); sub-
sequent discussion of the distribution of counts
refers to the sets of counts associated with a can-
cerous or noncancerous region.
Microvessel density provides information
about the distribution of the smallest blood ves-
sels, where Doppler ultrasonography detects
only larger vessels. The next question to be
answered was whether the presence of the larger
ultrasonographically visible blood vessels within
a cancer correlated with high microvessel counts.
To answer this question, various ultrasono-
graphic quantitative measures were computed
within each cancerous region and correlated
with the 90th-percentile microvessel count from
that same region. The cancerous regions were
separated by size; cancers with volumes greater
than 0.5 cm3 were labeled large, and those with
volumes less than 0.5 cm3 were labeled small.
Additionally, each prostate was classified as
either adverse disease, meaning it was found to
have cancer-positive margins, an extraprostatic
extension, or cancer-positive seminal vesicles, or
organ confined. The microvessel counts within
each prostate were subdivided by tissue type:
noncancerous, adjacent to cancer, Gleason
grades 4 and 5, Gleason grade 6, and Gleason
grades 7 to 9. The fraction of prostates with each
tissue type and a microvessel density greater
than 80 is reported in “Results.”
Results
The first results presented here were designed
to show what aspects of the ultrasonographic
color flow data provide information that will
aid in the detection of prostate cancer. As
described above, each prostate was divided
into 0.8-cm3 volumes that were either entirely
cancerous or noncancerous. The 4 basic mea-
sures, V, NMPCP, CPDfs, and CPDpm, were com-
puted within each volume. From these data, an
ROC analysis was performed (Fig. 3).
It can be readily seen that CPDfs was the best
basic measure for discriminating prostate can-
cer, with an accuracy of 80%. Both CPDpm and
V provided very little discriminating value,
with levels of accuracy of 58% and 54%,
respectively. NMPCP had an accuracy of 35%,
which implies that a low NMPCP correlates
with cancer (i.e., 1 – NMPCP had an accuracy
of 65%).
The second results combined the 2 basic
measures that showed promise, CPDfs and
NMPCP, into a Bayesian linear discriminator of
the form CPDfs – 3.3 ⋅ NMPCP. Figure 4 shows
the ROC curve of this measure compared with
those of CPDfs and 1/NMPCP. The accuracy of
CPDfs – 3.3 ⋅ NMPCP was 84%; it was signifi-
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Figure 3. Receiver operating characteristic curves of the 4 basic
measures. The CPDfs data did the best job of discriminating can-
cerous from noncancerous regions; CPDpm and V had little value
as discriminators; NMPCP actually showed an inverse relation-
ship to cancer. The 3 gray regions represent the 95% confidence
limits of the CPDfs curve, the CPDpm and V curves, and the
NMPCP curve, respectively. It can be seen that the differences
among the 3 sets of curves are significant.
cantly different from CPDfs at P = .07. Thus,
adding the information in NMPCP to CPDfs
did significantly improve the results.
Next, analysis of the microvessel density data
was performed. As described above, the
counts were made within the microscope field
that visually contained the most endothelial
stain within each 0.5-cm square that was
counted. This produced a wide distribution of
counts within each cancerous and noncancer-
ous region counted. The most distinctive
characteristic of cancerous microvessel
counts compared with noncancerous regions
was in the counts of more than 80 (Fig. 5).
This result implied that the best way to use
the microvessel density counts made in this
study was to characterize each cancerous
region by its highest counts. Next, the correla-
tion of the microvessel density information
with the ultrasonographic measures was ana-
lyzed. This was done by dividing each
prostate’s cancerous regions into large (>0.5
cm3) and small (<0.5 cm3) and computing the
mean ultrasonographic measures and 90th-
percentile count for each prostate’s divisions.
The results show that the ultrasonographic
measures were negatively correlated with the
high microvessel counts in the large cancers. A
correlation of –0.34 was obtained for speed-
weighted pixel density in large cancers, and a
correlation of –0.19 was obtained in small
cancers.
Mixed results were obtained when microvessel
density was investigated previously as a means
to determine the aggressiveness of cancer by
comparing it with surgical stage.6,14–19 In Table 1,
our results show that for this study a high
microvessel density was more likely to occur in
prostates that had organ-confined cancer.
Discussion
The purpose of this study was to determine
whether quantitative ultrasonographic color
flow measures provide information that could
be used to identify prostate cancer. It is impor-
tant to remember, however, that this study was
not designed to determine the clinical efficacy
of Doppler ultrasonography; therefore, the
results are intended to determine which of the
studied Doppler ultrasonographic measures is
best. Determining the effectiveness of the best
Doppler ultrasonographic measure for identi-
fying prostate cancer will be left to a future
study designed for that purpose.
That said, of the 4 basic quantitative ultra-
sonographic measures, CPDfs provided the
best discrimination of cancer in the prostate. It
is not readily apparent why CPDfs did so much
better than CPDpm at discriminating cancer. It
cannot be explained by the relative sensitivity
of the 2 modalities; globally, over all the
prostates, 16% of the voxels contained power
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Figure 4. Receiver operating characteristic curve of CPDfs combined
with NMPCP. The CPDfs data had accuracy (area under the curve) of
80.46%, and the reciprocal of NMPCP had accuracy of 64.75%.
The best linear combination of these measures was CPDfs – 3.3 ⋅
NMPCP, which had accuracy of 83.36%. The 1-sided P value that
this combined measure’s accuracy was better than that of CPDfs was
.07. This indicates that the information in the power mode values
does contribute to the discrimination of prostate cancer. Figure 5. Comparison of microvessel density distribution in can-
cerous and noncancerous regions. The distribution of counts
within cancerous regions from all prostates is shown to differ
significantly from the distribution range of noncancerous counts
(gray area) only at the highest counts (>80). Counts made in
regions adjacent to cancer did not deviate as much from the dis-
tribution range of noncancerous counts.
mode color, whereas only 10% had frequency
shift color. Power mode information is more
depth dependent than frequency shift informa-
tion; however, this information was probably
not a factor in the CPD measures, which were
bimodal in nature.
With the assumption that a majority of the
color pixels that exist in the frequency shift data
are common with the power mode, which is sup-
ported qualitatively by visual analysis of the data,
the only remaining explanation is that the addi-
tional 6% of color pixels seen in the power mode
have a confounding effect. Further analysis
aimed at identifying those pixels may provide
further insights and may help improve the utility
of the power mode for prostate cancer detection.
The mean value in the power mode (NMPCP)
had an ROC curve with an area of less than 50%
(35%), which means that low power values are
more indicative of cancer. This result is not
entirely surprising, because it suggests that the
smaller vessels, which have a lower power mode
signal, will be found in greater concentrations in
cancerous tissue. When the information con-
tained in NMPCP is added to that of CPDfs in a
Bayesian optimized linear combination, there is
an improvement, as shown in Figure 4. This
improvement is significant at P = 0.07 that the 2
areas are different. This result suggests that the
use of contrast agents, which would increase the
sensitivity of ultrasonography for visualizing
small vessels, could improve its ability to detect
prostate cancer.
It is still an area of debate whether microvessel
density is useful for classifying cancer. Typically,
studies of microvessel density investigate how
well it correlates with other prognostic indicators
such as the extent of cancer spread (organ con-
fined versus various degrees of adverse disease)
and Gleason grade. Microvessel density is not
used to differentiate cancer from noncancerous
tissue because other histologic methods exist for
that.
In this study, we wished to use microvessel
density to gain some understanding about the
distribution of blood vessels in and around can-
cers and how that relates to what is seen on
ultrasonography. First, the overall distribution of
microvessel density was looked at in both non-
cancerous and cancerous tissue of different clas-
sifications. It can be seen that the cancerous
distributions differ significantly from the non-
cancerous distributions only at the high end
(>80 microvessel counts per field). This means
that the most important information contained
in the microvessel density is found in the highest
counts within a given region, which is consistent
with the methods of other studies that used the
area of highest endothelial staining to character-
ize a whole cancerous region.14,15,18
When we looked at the fraction of different
classifications of cancer with counts of more
than 80, we saw that there was a correlation with
Gleason grade. However, organ-confined
tumors seemed to be more likely to have a high
count than the more dangerous adverse-disease
cancers.
Next, we looked at the correlation between
microvessel count (90th-percentile count within
a given cancer) and selected ultrasonographic
measures. In small cancers, the correlation was
almost 0, probably because of the poor signal-
to-noise ratio in both types of measures. In large
cancers, a small negative correlation was seen.
Both ultrasonographic and microvessel mea-
sures were on average greater in cancer than in
noncancerous tissue, so this negative correla-
tion implies that the cancers with high
microvessel density tend to have lower ultra-
sonographic measures and vice versa.
The correlation result was computed to test that
hypothesis. A positive correlation result would
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Table 1. Occurrence of High Microvessel Density With Respect to Stage and Grade
Noncancerous Adjacent Gleason 4 and 5 Gleason 6 Gleason 7–9
Extent of Cancer n % n % n % n % n %
Adverse disease 16 12.5 16 0.0 5 0.0 11 0.0 15 20.0
Organ confined 23 0.0 23 13.0 8 0.0 22 31.8 11 36.3
Shown are the percentages of prostates in this study with microvessel density counts of more than 80 in cancers of the given Gleason
grade range. Adjacent indicates microvessel counts made within the 0.5-cm squares adjacent to cancerous regions; n, total number of
prostates that had regions of that category; and %, percentage of prostates that had counts of more than 80 within that category. The
prostates were classified by surgical stage. It can be seen that the microvessel density is most likely to be high in organ-confined can-
cers of Gleason grade 7 and higher.
have supported that hypothesis with the argu-
ment that regions of high microvessel density cor-
relate with an overall increase in microvascularity,
which in turn correlates with a greater number of
large ultrasonographically visible vessels.
The negative correlation result that was
obtained indicates that we did not prove the
hypothesis that there would be a positive corre-
lation between cancers with high ultrasono-
graphically visible blood flow and high
microvessel density. However, it is difficult to
assign any further meaning to this result without
further analysis. For instance, one possible
explanation is that regions with high peak
microvessel density correlate with regions of low
average microvessel density. This explanation is
counterintuitive and would have to be tested
directly by computing the average microvessel
density. A more plausible explanation might be
that areas of highest microvascularity do not
occur near large vessels.
In summary, the 2 simple components of
Doppler ultrasonography that contribute to dis-
criminating prostate cancer from undiseased
prostate are CPDfs and negative NMPCP. The
failure to show a positive correlation between
microvessel counts and the ultrasonographic
measures indicates that if there is a relationship
between the blood flow measured by ultra-
sonography and the tiny vessels seen histologi-
cally, it is a complex relationship that would
require a more intricate series of studies to
understand.
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